Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

68Ga-FAPI PET in detection of 18F-FDG PET Negative Cholangiocarcinoma: A Case Report on Alternative Molecular Imaging in Biliary Tract Malignancy.

JPMA. The Journal of the Pakistan Medical Association·2025

Same author

Molecular profile of non-small cell lung cancer in a predominantly Black African population in Kenya: A single institution review.

Translational oncology·2025

Same author

Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes.

BJC reports·2024

Same author

Enhancing Postgraduate Medical Education: Upscaling and Recognition of Pakistan's Training.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2024

Same author

Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2024

Same author

Metastatic breast cancer in Kenya: survival, prognosis and management at a tertiary referral centre.

Ecancermedicalscience·2023

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Screening Ion Channels in Cancer Cells

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Old disease, new targets--part-I, solid malignancies.

Shiyam Kumar¹, Nehal Masood, Asim Jamal Shaikh

¹Section of Hematology/Oncology, Department of Medicine, The Aga Khan University Hospital, Karachi.

JPMA. the Journal of the Pakistan Medical Association

|June 19, 2009

Summary

Targeted cancer therapies like trastuzumab, bevacizumab, and cetuximab show promise. While generally safe, their high cost presents a challenge for developing nations.

Area of Science:

Oncology
Pharmacology

Background:

Targeted agents are increasingly vital in cancer treatment.
Trastuzumab is a key therapy for HER2-positive breast cancer, improving survival.
Bevacizumab (anti-VEGF MoAB) and cetuximab (anti-EGFR MoAB) are expanding roles in various cancers.

Purpose of the Study:

To review the established and emerging roles of targeted therapies in cancer treatment.
To highlight the efficacy and safety profiles of specific targeted agents.
To address the accessibility and cost considerations of these treatments in developing countries.

Main Methods:

Review of clinical trial data and established treatment guidelines.
Analysis of efficacy and survival data for key targeted agents.
Discussion of safety profiles and economic factors impacting treatment access.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Jun 22, 2026

Screening Ion Channels in Cancer Cells

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Main Results:

Trastuzumab demonstrates significant benefits in HER2-positive breast cancer.
Bevacizumab and cetuximab show efficacy across multiple cancer types, including colorectal cancer.
Sorafenib and sunitinib are effective in renal carcinoma and hepatocellular carcinoma.
Imatinib and sunitinib have roles in gastrointestinal tumors.

Conclusions:

Targeted therapies offer significant advancements in cancer care.
The safety profiles of these agents are generally favorable.
The high cost of targeted therapies remains a significant barrier, particularly for developing countries.